Mark Radzyner

1.0k total citations
13 papers, 810 citations indexed

About

Mark Radzyner is a scholar working on Economics and Econometrics, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark Radzyner has authored 13 papers receiving a total of 810 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Economics and Econometrics, 4 papers in Oncology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark Radzyner's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Economic and Financial Impacts of Cancer (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Mark Radzyner is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Economic and Financial Impacts of Cancer (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Mark Radzyner collaborates with scholars based in United States and Switzerland. Mark Radzyner's co-authors include David M. Rubin, Murray F. Brennan, James Dougherty, Edward L. Hannan, Mithat Gönen, Yuman Fong, David G. Pfister, Peter B. Bach, Elena B. Elkin and Ushma S. Neill and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer.

In The Last Decade

Mark Radzyner

13 papers receiving 794 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Radzyner United States 7 458 349 332 116 105 13 810
Kurt A. Campbell United States 12 371 0.8× 501 1.4× 254 0.8× 114 1.0× 30 0.3× 21 914
Yi‐Ju Chiang United States 14 362 0.8× 294 0.8× 322 1.0× 107 0.9× 56 0.5× 55 786
Emily S. Pavey United States 13 275 0.6× 213 0.6× 193 0.6× 48 0.4× 82 0.8× 23 765
Gregg P. Burleyson United States 7 540 1.2× 518 1.5× 582 1.8× 296 2.6× 62 0.6× 7 1.1k
Rebecca M. Dodson United States 21 554 1.2× 861 2.5× 469 1.4× 196 1.7× 50 0.5× 30 1.3k
María Eberg Canada 14 341 0.7× 230 0.7× 339 1.0× 175 1.5× 70 0.7× 32 1.0k
Kota Sahara United States 20 675 1.5× 724 2.1× 489 1.5× 135 1.2× 83 0.8× 82 1.2k
H.S. Snijders Netherlands 18 727 1.6× 564 1.6× 257 0.8× 219 1.9× 42 0.4× 30 994
N. Maisey United Kingdom 15 671 1.5× 265 0.8× 326 1.0× 31 0.3× 96 0.9× 30 1.1k
Jillian K. Smith United States 13 384 0.8× 294 0.8× 188 0.6× 27 0.2× 46 0.4× 22 690

Countries citing papers authored by Mark Radzyner

Since Specialization
Citations

This map shows the geographic impact of Mark Radzyner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Radzyner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Radzyner more than expected).

Fields of papers citing papers by Mark Radzyner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Radzyner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Radzyner. The network helps show where Mark Radzyner may publish in the future.

Co-authorship network of co-authors of Mark Radzyner

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Radzyner. A scholar is included among the top collaborators of Mark Radzyner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Radzyner. Mark Radzyner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Lipitz‐Snyderman, Allison, Michael Curry, David M. Rubin, et al.. (2019). Cancer hospital advertising and outcomes: trust the messenger?. The Lancet Oncology. 20(6). 760–762. 4 indexed citations
2.
Lipitz‐Snyderman, Allison, et al.. (2019). A conundrum in cancer quality measurement: Performance on long-term survival reflects performance a long time ago.. Journal of Clinical Oncology. 37(15_suppl). e18222–e18222. 1 indexed citations
3.
Schleicher, Stephen M., Jessica A. Lavery, Brooke Barrow, et al.. (2018). Cancer survival in the context of growing hospital participation in Medicare ACOs.. Journal of Clinical Oncology. 36(15_suppl). 6543–6543. 1 indexed citations
4.
Pfister, David G., David M. Rubin, Elena B. Elkin, et al.. (2015). Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage. JAMA Oncology. 1(9). 1303–1303. 93 indexed citations
5.
Brennan, Murray F., Mark Radzyner, & David M. Rubin. (2009). Outcome—more than just operative mortality. Journal of Surgical Oncology. 99(8). 470–477. 18 indexed citations
6.
Fong, Yuman, Mithat Gönen, David M. Rubin, Mark Radzyner, & Murray F. Brennan. (2005). Long-Term Survival Is Superior After Resection for Cancer in High-Volume Centers. Annals of Surgery. 242(4). 540–547. 303 indexed citations
7.
Sherman, Eric J., David M. Rubin, Ennapadam Venkatraman, et al.. (2004). Using Patients As Their Own Controls for Cost Evaluation of Phase I Clinical Trials. Journal of Clinical Oncology. 22(7). 1308–1314. 3 indexed citations
8.
Hannan, Edward L., Mark Radzyner, David M. Rubin, James Dougherty, & Murray F. Brennan. (2002). The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. Surgery. 131(1). 6–15. 315 indexed citations
9.
Sherman, Eric J., David G. Pfister, Hirsch S. Ruchlin, et al.. (2001). The collection of indirect and nonmedical direct costs (COIN) form. Cancer. 91(4). 841–853. 1 indexed citations
10.
Sherman, Eric J., David G. Pfister, Hirsch S. Ruchlin, et al.. (2001). The collection of indirect and nonmedical direct costs (COIN) form. Cancer. 91(4). 841–853. 29 indexed citations
11.
Radzyner, Mark, et al.. (1994). Ciprofloxacin in respiratory tract infections: A phase IV surveillance study. Current Therapeutic Research. 55(7). 729–735. 1 indexed citations
12.
13.
Radzyner, Mark, et al.. (1979). Effects of glucagon, vasoactive intestinal peptide (VIP) and lysine-vasopressine on villous microcirculation and superior mesenteric artery blood flow of the rat.. PubMed. 129–31. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kurt A. Campbell Breakdown of academic impact, for papers by Yi‐Ju Chiang Breakdown of academic impact, for papers by Emily S. Pavey Breakdown of academic impact, for papers by Gregg P. Burleyson Breakdown of academic impact, for papers by Rebecca M. Dodson Breakdown of academic impact, for papers by María Eberg Breakdown of academic impact, for papers by Kota Sahara Breakdown of academic impact, for papers by H.S. Snijders Breakdown of academic impact, for papers by N. Maisey Breakdown of academic impact, for papers by Jillian K. Smith
Rankless by CCL
2026